Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns. (November 2014)

• Record Type: Journal Article
• Authors: Abdel-Rahman, Omar; ElHalawani, Hesham
• Is Part Of: Expert opinion on drug safety. Volume 13:Number 11(2014)
• Page Start: 1443
• Page End: 1467
• Publication Date: 2014-11
• Subjects: breast cancer -- chemotherapy -- elderly -- endocrine therapy; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1517/14740338.2014.955848
• Languages: English
• ISSNs: 1474-0338

Abstract

Abstract : Introduction: The issue of systemic treatment for early breast cancer in the elderly has always been challenging and in spite of the clear evidence of the potential benefits of adjuvant treatment in older women, they are usually undertreated with the potential consequence of worse outcomes. Areas covered: This article will review the evidence surrounding the various systemic options in the treatment armamentarium of early-stage breast cancer in elderly patients. The risks and benefits, with particular attention to a number of newly introduced targeted agents, along with the potential role of incorporating a combined geriatric/oncologic assessment as a routine part of the management of elderly patients with breast cancer are considered. Expert opinion: Administration of available options for (neo)adjuvant endocrine, chemo, as well as targeted therapeutics in fit elderly patients is feasible and tolerable; however, a routine input from geriatric medicine and psycho-oncology experts as well as the training of specialized oncology staff with special interest in geriatric oncology are believed to improve the outcome of elderly patients.